Clinical Trial Update: Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab as a single agent in advanced adrenocortical carcinoma has posted results. The study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-01-06